ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00500058
Recruitment Status : Completed
First Posted : July 12, 2007
Last Update Posted : July 26, 2017
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline